ScieniQ Publishers

Journal of Neurology and Neuroscience Research

Review Article

Mechanisms and Clinical Implications of Allergy-Assisted Immunotherapy for Tumor Neurogenesis

Michael John Dochniak

Forest Lake, Minnesota, 55025, USA

*Corresponding author
Michael John Dochniak Forest Lake, Minnesota, 55025, USA

Received: 21 April 2026
Accepted: 28 April 2026
Published: 11 May 2026

Abstract

Tumor neurogenesis—the growth of new nerve fibers within solid tumors—plays a pivotal role in cancer progression, metastasis, and immune escape by fostering a supportive neural microenvironment. Traditional immunotherapies often falter against these neural networks, limiting their therapeutic impact. Emerging research points to allergy-assisted cancer immunotherapy (AACI), particularly leveraging acute IgE-mediated allergic responses, as a disruptive approach to sever nerve-tumor crosstalk. By inducing localized allergic inflammation, AACI can transform immunologically "cold" tumors into "hot" ones that are more susceptible to immune attack. This review synthesizes mechanistic insights, preclinical advances, and clinical potential for AACI as a next-generation strategy to overcome immune resistance and improve outcomes for patients with solid cancers.

Keywords: Tumor Neurogenesis; Allergy-Assisted Cancer Immunotherapy (AACI); Tertiary Lymphoid Structures; Tumor Microenvironment (TME); Mast Cell–Nerve Interaction; Acute Allergic Response

Introduction

The link between neuroscience and oncology reveals a key role for the nervous system in shaping the tumor microenvironment, influencing cancer progression, metastasis, and immune evasion. Tumor neurogenesis—the growth of new nerve fibers within tumors—promotes malignancy and shields cancer cells from immune attack. Traditional immunotherapies can be thwarted by these neural networks, underscoring the need for innovative strategies.

Recent research indicates that harnessing acute IgE-mediated allergic responses may disrupt nerve-tumor crosstalk. Such responses unleash pro-inflammatory cytokines, histamine, and activate immune cells, which can remodel the tumor microenvironment and suppress neurogenesis. Allergy-assisted cancer immunotherapy (AACI) aims to convert "cold" tumors into "hot" ones to enhance susceptibility to immune-mediated destruction [1].

This review outlines the mechanistic rationale, preclinical data, and therapeutic potential of allergy-assisted immunotherapy to target tumor neurogenesis and improve outcomes in patients with solid malignancies.

Description

Allergy-assisted immunotherapy is an innovative cancer treatment targeting tumor neurogenesis—the process by which tumors recruit new nerve fibers to support growth and evade the immune system. This section discusses the mechanistic basis, preclinical findings, and potential clinical uses of leveraging acute allergic responses, especially IgE-mediated pathways, to disrupt nerve-tumor crosstalk. Localized allergic inflammation in the tumor microenvironment can suppress neurogenesis, convert "cold" tumors into "hot" ones, and enhance the efficacy of existing immunotherapies. Current research shows that allergy-assisted immunotherapy could redefine cancer treatment paradigms and offer hope for improved outcomes in solid malignancies [1].

Mechanisms and Clinical Implications of Allergy-Assisted Immunotherapy for Tumor Neurogenesis

Tumor neurogenesis, the process by which tumors recruit new nerve fibers, significantly contributes to cancer progression, metastasis, and immune evasion. Emerging research highlights that triggering acute IgE-mediated allergic inflammation can disrupt this neural support, remodel the tumor microenvironment, and suppress tumor growth [2].

Mechanistically, allergy-induced immune activity mobilizes eosinophils, T cells, and natural killer cells, making immunologically "cold" tumors more responsive to immune attack. Histamine and other mediators released during allergic reactions can impair the survival and outgrowth of tumor-associated nerve fibers. Mast cells, abundant near nerves within tumors, are central to these processes; allergy-assisted approaches may disrupt mast cell–nerve interactions, reduce tumor innervation, and enhance anti-tumor immunity [3].

A study indicates that allergy-assisted cancer immunotherapy (AACI) can drive the formation of Tertiary Lymphoid Structures [49], foster immune cell infiltration, and diminish tumor growth, in part by interfering with neurogenic pathways. This approach offers a promising avenue to enhance the effectiveness of immune checkpoint inhibitors and overcome tumor immune resistance. Allergy-assisted passive immunotherapy—utilizing allergen-specific IgE and controlled allergen exposure—can trigger robust inflammatory responses in the tumor microenvironment, further amplifying anti-neurogenic and anti-tumor effects [1].

In summary, allergy-assisted immunotherapeutic strategies represent a novel and multifaceted approach to targeting tumor neurogenesis. Leveraging the body's allergic response, these methods seek to disrupt nerve-tumor crosstalk, remodel the tumor microenvironment, and improve outcomes for patients with solid malignancies.

Tumor Neurogenesis and Axonogenesis: Mechanisms and Clinical Implications

Tumors often initiate a "neurogenic switch," recruiting nerve fibers to promote spread and growth. Triggering localized allergic reactions may mobilize immune cells to target and eliminate tumor-associated nerve fibers, disrupting neural support of malignancy [4].

Acute allergic inflammation promotes the infiltration of eosinophils and T cells, and the activation of natural killer cells, transforming the tumor microenvironment from immunologically "cold" to "hot." This heightened immune activity is associated with reduced neurogenesis and tumor progression, suggesting new avenues for therapeutic intervention [5].

Histamine, a key mediator in allergic responses, can influence neurogenesis by acting on histamine receptor 1, possibly impairing the survival and growth of immature neurons, especially during tumor-related inflammation [6].

Mast cells found near nerve fibers help modulate neuronal function in tumors. Acute allergic responses may disrupt mast cell–nerve interactions, reduce tumor innervation, and support anti-tumor immunity. Natural killer cells activated by allergic inflammation add to tumor regression by increasing immune responses against cancer cells [7].

A study suggests that allergy-assisted cancer immunotherapy (AACI) uses IgE-mediated responses to treat tumors. AACI may promote the formation of Tertiary Lymphoid Structures [49], boost immune cell infiltration, and slow tumor growth, in part by disrupting neurogenesis. This "allergic" pathway could turn "cold" tumors "hot" and improve the efficacy of immune checkpoint inhibitors (ICIs) [8].

Allergy-assisted passive immunotherapy delivers allergen-specific IgE to patients, followed by controlled allergen exposure to trigger mast cell degranulation, histamine release, and cytokine production in the tumor microenvironment (TME). The acute inflammation induced by this protocol may stimulate the formation of Tertiary Lymphoid Structures in solid tumors [49]. TLS coordinates adaptive immunity, facilitating B and T cell interactions and often improving prognosis [1].

Studies suggest that this "allergic reaction" in the tumor can increase immune cell infiltration and counteract tumor-induced tolerance. [1, 9-11]. While traditional immunotherapy often focuses on T cells, this method leverages the IgE-mediated immune response to enhance the recruitment and activation of CD8+ T cells. Some studies suggest that allergy-driven immune responses may be associated with beneficial outcomes in solid tumors and may interfere with the nerve-tumor crosstalk (anti-neurogenesis) [3,12-16].

Aggressive solid tumors orchestrate both neurogenesis and axonogenesis to recruit nerve fibers that support their growth, invasion, and metastatic spread. Neurogenesis refers to the recruitment of neural progenitor cells from the central nervous system, which migrate and integrate into the tumor, forming new neurons. In parallel, axonogenesis describes the sprouting of new peripheral nerve endings directly into the tumor microenvironment. These processes create a pro-tumorigenic niche, reinforcing the tumor's malignant potential and complicating therapeutic intervention [4].

Mechanisms of Tumor Innervation

Tumor innervation is a dynamic, bidirectional process where cancer cells actively recruit and manipulate the nervous system to facilitate progression. Through the secretion of neurotrophic factors such as NGF and BDNF [17], tumors stimulate the outgrowth of various nerve types, while more aggressive cancers may even recruit neural progenitor cells from the brain to populate the tumor microenvironment [18]. This recruitment is further enhanced by exosomal reprogramming [19], which can transform sensory nerves into tumor-promoting adrenergic fibers. Collectively, these mechanisms establish a "crosstalk" that not only drives tumor growth and immune evasion but also provides physical pathways for metastasis and contributes to chronic cancer pain.

Impact on Tumor Progression

Nerves actively fuel cancer progression by acting as both biological signaling hubs and physical pathways for spread. High nerve density within a tumor often predicts a more aggressive disease and a higher risk of metastasis [20].

Specifically, adrenergic nerves release chemicals like noradrenaline to trigger the growth of new blood vessels [21] while simultaneously signaling the brain to suppress immune cell activity, effectively shielding the tumor [17].

Furthermore, cancer cells can physically hijack these nerves, using them as low-resistance highways to reach distant organs via a process known as perineural invasion [22].

Clinical Significance and Therapeutic Implications

The emerging field of cancer neuroscience and AllergoOncology suggests that the "nerve-cancer axis" can be disrupted by triggering localized allergic reactions within the tumor microenvironment. This strategy, known as Allergy-Assisted Cancer Immunotherapy (AACI), leverages IgE-mediated responses to break the tumor's immunosuppressive shield and physically disrupt its structure through vasodilation. By repurposing mast cells and releasing neurotoxic mediators like EDN, this approach aims to "unplug" the hijacked nerve fibers that tumors use to grow and spread, effectively turning the body's natural allergic machinery into a precision weapon against malignancy.

- **Breaking Tolerance:** Tumors often create an immunosuppressive "bubble." An allergic surge causes rapid vasodilation and physical disruption, potentially making the tumor visible to the immune system again [15].
- **Reprogramming Macrophages:** Allergic responses can shift macrophages from a pro-tumor state to a state that might recruit more aggressive immune attackers [23].
- **Anti-Neurogenesis:** Tumors often "hijack" nerve fibers to grow and spread. Since mast cells and nerves live in close proximity, an allergic reaction could theoretically sever those signaling pathways or release neurotoxic mediators, such as eosinophil-derived neurotoxin (EDN), to stunt that growth [24-27].

Suppression of Tumor Neurogenesis

Tumor neurogenesis and axonogenesis (nerve sprouting) are critical for cancer progression, as infiltrating nerves release neurotransmitters, such as norepinephrine [26], that stimulate angiogenesis and promote immune evasion. AACI suppresses these processes through several mechanisms:

Mast Cell Reprogramming: Instead of reacting to allergens like pollen, mast cells are "retrained" with tumor-specific IgE. When these cells infiltrate a tumor, they release rapid bursts of inflammatory mediators that can disrupt the neurotrophic signals (like NGF and BDNF) that cancer cells use to recruit nerves [28].

Microenvironmental Remodeling: The "allergy-like" reaction triggered within the tumor transforms "cold" tumors (immune-suppressed) into "hot" ones. This shift towards a pro-inflammatory state often inhibits M2-like macrophages, which normally support nerve growth and tumor expansion [15].

Neuro-Immune Crosstalk Interruption: By activating Natural Killer (NK) cells and cytotoxic T cells, AACI may eliminate tumor cells that secrete axonal guidance molecules (e.g., EphrinB1) that facilitate nerve infiltration [29,30].

Enhancement of Patient Outcomes

Suppressive therapies that target tumor-associated nerves, such as allergy-assisted modulation and HRH1 inhibition [31,32], and alleviate chronic cancer pain [33]. By dismantling the neural infrastructure within the tumor microenvironment, these methods not only improve survival rates in aggressive cancers like melanoma and lung cancer but also significantly enhance a patient's overall quality of life.

Decoupling Allergic Inflammation from Systemic Toxicity

AllergoOncology can be used to transform the risk of systemic anaphylaxis into a controlled, localized "allergy-on-demand" within the tumor microenvironment. By using precision-engineered IgE and bispecific antibodies, the strategy bypasses traditional immune checkpoints and "liquefies" the tumor's protective neural and structural barriers through mast cell-driven inflammation. This not only turns "cold" tumors "hot" by disrupting the stroma but also leverages IgE's unique ability to enhance dendritic cell antigen presentation, creating a bridge between acute allergic destruction and long-term, adaptive T-cell surveillance [34,35].

Strategic Reprogramming of the Neuro-Immune Axis

Strategic reprogramming of the neuro-immune axis [36] reverses the tumor's suppressive control over the nervous system, enabling the immune system to treat cancer infrastructure as an allergen. By inducing IgE-activated mast cells to destroy neural-stromal barriers, this approach converts "cold" tumors into "hot" zones for improved T-cell infiltration [37].

Enhancing Long-Term Adaptive Surveillance

Integrating IgE-facilitated antigen presentation transforms a transient allergic reaction into a robust, long-term immune defense by bridging the gap between acute inflammation and adaptive memory. By leveraging the high affinity of IgE for receptors on Dendritic Cells, antigen uptake is boosted by up to 1,000-fold, allowing the immune system to detect even trace tumor markers and trigger a potent secondary T-cell response [38]. This process further drives epitope spreading [39], where the immune system learns to recognize a broader array of tumor markers beyond the initial target, effectively preventing tumor escape and ensuring a comprehensive, self-sustaining surveillance loop.

Overcoming Natural Inhibitory Checkpoints

Allergy-assisted Cancer Immunotherapy (AACI) offers a unique therapeutic advantage by bypassing the natural inhibitory checkpoints, such as FcγRIIb, that typically dampen IgG-based treatments. Because IgE antibodies lack known inhibitory Fc receptors, they provide a high-fidelity, "unfiltered" immune signal that remains functional even within the immunosuppressive tumor microenvironment. By leveraging the Th2/allergic pathway—which is evolutionarily adapted to operate in hostile, high-barrier tissues—AACI can dismantle a tumor's neural and structural defenses without being prematurely shut down by the metabolic "off-switches" that hinder traditional T-cell-based therapies [40].

Precision IgE Engineering

Precision IgE engineering aims to convert the body's allergic response into a targeted anti-tumor attack, mitigating systemic anaphylaxis risks. Through bispecific formats [41], IgE-IgG hybrids [42], and glycosylation modifications [43], researchers are improving tumor-specific degranulation, stability, and manufacturability to achieve a controlled immune response.

Strategic "Denervation" Combinations

Strategic "denervation" combinations aim to dismantle the nerve-cancer axis by simultaneously blocking chemical signals and physically reducing nerve density within the tumor microenvironment. This approach pairs AllergoOncology (using IgE-mediated anti-neurogenesis to "prune" nerves) with pharmacological blockers, such as H1 antihistamines [44] or beta-blockers [45], to "silence" pro-tumor signaling. By neutralizing histamine's immunosuppressive effects on T cells and cutting off the neural "hardware" tumors use to thrive, this synergy transforms the microenvironment from a sanctuary for growth into a landscape primed for immune-mediated destruction.

Boosting Adaptive Memory

This strategy transforms an acute "allergic shock" into a permanent immune defense by leveraging IgE-mediated antigen presentation to boost T-cell memory by up to 1,000-fold [38]. By utilizing the resulting inflammatory burst to seed Tertiary Lymphoid Structures directly within the tumor, the site is converted from an immunosuppressive environment into an active "hot" battleground [46, 49]. This effectively uses the allergic response as a super-adjuvant, ensuring long-term surveillance and preventing cancer from recurring.

Advanced Monitoring & Biomarkers

Advanced monitoring, including multimodal imaging [47] and Basophil Activation Tests (BAT) [48], enhances the "neurogenic switch" approach by enabling precise, real-time data to guide oncology and allergy treatments. These tools transition clinical strategies toward high-precision, individualized, and safer interventions by mapping tumor innervation and assessing patient-specific reaction risks.

Conclusion

AllergoOncology-induced anti-neurogenesis offers a promising and innovative approach to disrupt the intricate nerve-tumor interactions that drive cancer growth, metastasis, and immune escape. By harnessing the body's allergic mechanisms—especially IgE-mediated responses—this strategy not only remodels the tumor microenvironment and suppresses neurogenesis but also enhances the effectiveness of current immunotherapies. As research in allergy-assisted cancer immunotherapy advances, there is significant potential to translate these insights into novel clinical interventions that could transform treatment paradigms, curb tumor progression, and ultimately improve survival and quality of life for patients with solid malignancies.

Compliance with ethical standards

Acknowledgments

Artificial intelligence technology was used in the preparation of this review article. Gemini AI (version 2.5 Pro, Google LLC, Mountain View, CA) was used during the research period of April 2026.

Grammarly was used for grammar, spelling, and punctuation throughout the preparation of the review article. The tool (Grammarly, version 14.1271.0, Grammarly Inc., San Francisco, CA) was used to review and edit the entire review article for grammatical accuracy, clarity, and readability. Grammarly's AI-powered writing assistant provided suggestions on sentence structure, word choice, and tone consistency, which the author reviewed and selectively incorporated. The tool was not used to generate original scientific content, data analysis, or research conclusions. The author takes full responsibility for the integrity of all content generated and presented in this review article.

Disclosure of conflict of interest

The author claims no conflict of interest.

References

1. Dochniak MJ. (2025) Allergy-assisted passive immunotherapy: Harnessing IgE-mediated responses for cancer treatment.GSC Biological and Pharmaceutical Sciences, 30: 385-387.
2. Di Gioacchino M, Della Valle L, et al. (2022) AllergoOncology: Role of immune cells and immune proteins. Clin Transl Allergy. Mar;12: e12133.
3. huaxia (2025) "Chinese scientists use allergy-like immune response for cancer therapy" Xinhua, Available: https://english.news.cn/20251210/e282addb917040c2b96cb87473cba8ff/c.html#:~:text=The%20allergy%2Dlike%20reaction%20inside,rapidly%20create%20a%20personalized%20therapy. Accessed 21 April 2026.
4. Cervantes-Villagrana RD, Albores-García D, et al. (2020) Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. Jun 18;5: 99.
5. Zhou Y, Li L, Zhou D, et al. (2023) Natural killer cells contribute to 'hot' tumor regression in the allergic inflammatory environment. Int Immunopharmacol. Oct;123: 110760.
6. Chen J, Liu G, et al. (2022) Glioblastoma stem cell-specific histamine secretion drives pro-angiogenic tumor microenvironment remodeling. Cell Stem Cell. Nov 3;29: 1531-1546.e7.
7. Zhou Y, Li L, et al. (2023) Natural killer cells contribute to 'hot' tumor regression in the allergic inflammatory environment. Int Immunopharmacol. Oct;123: 110760.
8. Markov SD, Caffrey TC, et al. (2021) IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Mol Cancer Ther. Dec;20: 2457-2468.
9. Dochniak MJ. (2025) Allergic Reactions and Solid Tumors. GSC Biological and Pharmaceutical Sciences, 31: 168-170.
10. Peyraud F, Guegan JP, et al. (2025) Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside. Med. Jan 10;6: 100546.
11. Martín-Cruz L, Palomares O. (2025) Allergen-Specific Immunotherapy and Trained Immunity. Allergy. Mar;80: 677-689.
12. Trüb M, Zippelius A. (2021) Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies. Front Immunol. May 12;12: 674565.
13. Zhang Q, Wu S. (2023) Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. Front Immunol. Jan 11;13: 1063711.
14. Dochniak MJ. (2025) Combinational cancer immunotherapy: Allergy-assisted immunotherapy and immune checkpoint inhibitors. GSC Biological and Pharmaceutical Sciences, 31: 131-133.
15. Jensen-Jarolim E, Bax HJ, et al. (2018) AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy. Feb;73: 328-340.
16. Pan Z, Zhang S, et al. (2025) The association between allergy and risk of brain tumors: Evidence from 40 observational studies. Acta Neurochir (Wien). Apr 21;167: 111.
17. Zhang, S., Yuan, L. et al. (2026) Cancer neuroscience: signaling pathways and new therapeutic strategies for cancer. Sig Transduct Target Ther 11, 66.
18. Mauffrey P, Tchitchek N, et al. (2019) Progenitors from the central nervous system drive neurogenesis in cancer. Nature. May;569: 672-678.
19. Amit M, Takahashi H, et al. (2020) Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 2020 Feb;578: 449-454.
20. Schmitd LB, Perez-Pacheco C, et al. (2021) Nerve density in cancer: Less is better. FASEB Bioadv. Jul 11;3: 773-786.
21. Zahalka, A. H., et al. (2017). "Adrenergic nerves activate an angio-metabolic switch in prostate cancer." Science, 358: 321-326.
22. Liebig, C., Ayala, G. et al. (2009) Perineural invasion in cancer. Cancer, 115: 3379-3391.
23. Josephs DH, Bax HJ, et al. (2017) Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling. Cancer Res. Mar 1;77: 1127-1141.
24. Yun HD, Goel Y, et al. (2023) Crosstalk of Mast Cells and Natural Killer Cells with Neurons in Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. Aug 8;24: 12543.
25. Jobling P, Pundavela J, et al. (2015) Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression. Cancer Res. 2015 May 1;75: 1777-81.
26. Carretero R, Sektioglu IM, et al, (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. Jun;16: 609-17.
27. Ligan C, Ma XH, et al. (2024) The regulatory role and mechanism of mast cells in tumor microenvironment. Am J Cancer Res. Jan 15;14: 1-15.
28. Xu Y, Zhang X, et al, (2026) Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. Cell. Feb 5;189: 872-886.e23.
29. Vermeer PD, Restaino AC, et al, (2025) Nerves at Play: The Peripheral Nervous System in Extracranial Malignancies. Cancer Discov. Jan 13;15: 52-68.
30. Silverman DA, Martinez VK, et al, (2021) Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. Cancer Res. Mar 15;81: 1431-1440.
31. Li H, Xiao Y, et al, (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. Jan 10;40: 36-52.e9.
32. Cole SW, Nagaraja AS, et al, (2015) Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer. Sep;15: 563-72.
33. Ali SR, Jordan M, et al, (2022) Nerve Density and Neuronal Biomarkers in Cancer. Cancers (Basel). Oct 1;14: 4817.
34. Morris A. (2024) Decorated nanoparticles prevent allergic reactions. Northwestern University. Available: https://news.northwestern.edu/stories/2024/01/decorated-nanoparticles-prevent-allergic-reactions-Accessed 4 April 2026.
35. Spicer, J. et al. (2023) Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours. Nature Communications, 14: 4180.
36. Zhang Y, Yuan Y, et al. (2025) The Bridging Role of Schwann Cells in the Interaction between Tumors and the Nervous System: A Potential Target for Cancer Therapy. Mol Cancer Res. Jun 3;23: 494-502.
37. Chen L, Jin Yu-Xuan, et al. (2026) IgE-Sensitized Mast Cells: A Programmable Platform for Antigen-Triggered Oncolytic Virotherapy, ResearchGate 5:1.
38. latzer B, Elpek KG, et al. (2015) IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. Cell Rep. Mar 10;10: 1487-1495.
39. Vanderlugt, CL, Miller, SD, (2002). Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nature Reviews Immunology, 2: 85-95.
40. Jensen-Jarolim E, Bax HJ, et al. (2017) AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy. Jun;72: 866-887.
41. Vukovic N, Halabi S, et al. (2022) A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes. J Biol Chem. Aug;298: 102153.
42. Grandits M, Palhares LCGF, et al. (2025) Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality. MAbs. Dec;17: 2502673.
43. Edwards E, Livanos M, et al. (2022) Strategies to control therapeutic

antibody glycosylation during bioprocessing: Synthesis and separation. Biotechnol Bioeng. Jun;119: 1343-1358.
44. Li H, Xiao Y, et al. (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. Jan 10;40: 36-52.e9.
45. Koh (2025) Pancreatic cancer: blocked nerves as a possible new treatment strategy. German Cancer Research Center. Available: https://www.dkfz.de/en/news/press-releases/detail/pancreatic-cancer-blocked-nerves-as-a-possible-new-treatment-strategy Accessed 4 April 2026.
46. Bangs DJ, Hondowicz B, et al (2025) Tertiary lymphoid structures support the development of allergen-specific progenitor CD4+ T cells. bioRxiv [Preprint]. Oct 5:2025.10.03.680350.
47. Cassim S, Montemagno C. (2026) Neural Innervation of Tumors: Mechanisms, Hallmarks, and Therapeutic Opportunities. Cancers (Basel). Mar 25;18: 1063.
48. Arasi S, Niegowska M et al. (2026) Basophil activation test (BAT): Clinical and research relevance in allergy diagnostics. Italian Journal of Pediatric Allergy and Immunology. Issue 1. March 27.
49. Dochniak MJ. (2026) Superallergen-Assisted passive cancer immunotherapy and tertiary lymphoid structures. GSC Advanced Research and Reviews. 27: 055-058.

Cite this article: Michael John Dochniak. (2026) Mechanisms and Clinical Implications of Allergy-Assisted Immunotherapy for Tumor Neurogenesis. Journal of Neurology and Neuroscience Research 7(2): 225-229.